Physiomics (PYC) AI Stock Analysis

• Market Cap: £848.98K
• Dividend Yield: N/A
• Average Volume (3M): 2.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: 44.32%
• EPS Growth: 60.00%
• Country: UK
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 303,208,700
• 10 Day Avg. Volume: 1,168,038
• 30 Day Avg. Volume: 2,434,740
• PEG Ratio: 0.33
• Price to Book (P/B): 5.75
• Price to Sales (P/S): 2.99
• P/FCF Ratio: -2.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: 0.28p ▼(-0.71% Downside)

The score is held back primarily by weak financial performance (continued losses and cash burn despite revenue growth) and a bearish technical setup (below major moving averages with negative MACD). Offsetting factors include a clean, no-debt balance sheet and positive corporate updates around new/follow-on contracts and team retention, but these are not yet reflected in profitability or cash generation.

Positive Factors

New Contracts

Securing new contracts with established biotech firms like Numab Therapeutics enhances Physiomics' market position and long-term growth prospects by expanding its client base and reinforcing its role as a trusted partner in drug development.

Strategic Growth Initiatives

The launch of new service lines and strategic growth initiatives, such as biostatistics and personalized medicine tools, positions Physiomics to capture more market opportunities and diversify its revenue streams, supporting sustainable long-term growth.

Debt-Free Status

Maintaining a debt-free status provides Physiomics with greater financial flexibility and reduces risk, allowing the company to invest in growth opportunities without the burden of interest payments, which is crucial for long-term stability.

Negative Factors

Declining Revenues

Consistently declining revenues and negative profit margins indicate operational challenges and inefficiencies, which can hinder the company's ability to invest in growth and innovation, impacting its long-term competitiveness and financial health.

Negative Cash Flow

Negative cash flow highlights cash management issues, limiting Physiomics' ability to fund operations and strategic initiatives internally, which could strain resources and affect its capacity to sustain growth over time.

Equity Decline

A decline in stockholders' equity reflects reduced financial stability and a decreased ability to cover liabilities, which can undermine investor confidence and limit the company's ability to secure favorable financing for future projects.

Physiomics Business Overview & Revenue Model

Company Description

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.

How the Company Makes Money

Physiomics makes money through service contracts with pharmaceutical and biotechnology companies, providing them with advanced modeling and simulation services to enhance their drug development processes. The company's key revenue streams are consultancy fees for their predictive modeling services, particularly in oncology, and licensing fees for their proprietary Virtual Tumor technology. Significant partnerships with leading pharmaceutical companies, which leverage Physiomics' expertise to accelerate and de-risk their drug development pipelines, contribute substantially to the company's earnings.

Physiomics Financial Statement Overview

Summary

Physiomics faces significant financial challenges with declining revenues, negative profit margins, and deteriorating cash flows. Despite being debt-free, the reduction in equity and persistent losses highlight the need for strategic improvements.

Income Statement

Physiomics has faced declining revenue over the years, with a negative revenue growth rate from 2023 to 2024. The company has consistently reported negative gross profit and net income, leading to unfavorable gross and net profit margins. The persistent negative EBIT and EBITDA margins further indicate operational challenges and inefficiencies.

Balance Sheet

The company has managed to maintain a debt-free status, which is a positive aspect. However, the significant decline in stockholders' equity from 2023 to 2024 raises concerns about financial stability. The equity ratio has also decreased, reflecting a reduced ability to cover liabilities with equity.

Cash Flow

Physiomics has experienced deteriorating operating cash flow, with negative free cash flow reported consistently. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is unfavorable, highlighting cash management issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	784.00K	543.25K	597.35K	830.27K	702.31K
Gross Profit	-435.08K	-677.43K	-581.62K	-429.01K	-365.79K
EBITDA	-448.21K	-659.80K	-561.57K	-347.84K	-324.52K
Net Income	-415.25K	-609.35K	-477.26K	-253.14K	-215.83K
Balance Sheet
Total Assets	892.03K	422.60K	674.39K	1.12M	1.32M
Cash, Cash Equivalents and Short-Term Investments	461.24K	191.07K	416.59K	687.67K	1.04M
Total Debt	0.00	3.83K	7.35K	0.00	0.00
Total Liabilities	199.85K	140.08K	142.67K	140.61K	157.57K
Stockholders Equity	692.17K	282.53K	531.72K	974.81K	1.17M
Cash Flow
Free Cash Flow	-550.08K	-565.44K	-271.50K	-358.62K	-48.65K
Operating Cash Flow	-546.14K	-548.13K	-264.86K	-349.25K	-32.50K
Investing Cash Flow	-3.41K	-15.21K	-6.22K	-9.37K	-16.15K
Financing Cash Flow	819.73K	337.83K	0.00	2.85K	44.24K

Physiomics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PYC, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.33, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 30.78 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PYC.

Physiomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	58 Neutral	£10.66M	-6.18	-15.57%	―	13.32%	55.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PYC	45 Neutral	£848.98K	-1.56	-85.21%	―	44.32%	60.00%
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
OPTI	43 Neutral	£6.56M	-45.36	-2.42%	―	―	―
VAL	41 Neutral	£2.86M	-0.27	―	―	418.49%	27.86%
OBD	38 Underperform	£12.66M	-0.31	-407.49%	―	72.17%	79.03%

Physiomics Corporate Events

Physiomics Grants Premium-Priced Options to Biometrics Head to Support Growth Strategy

Physiomics has granted a total of 4,548,132 share options under its existing option scheme, including a new award of 4,548,132 options to Head of Biometrics Jesse Thissen, structured across three tranches with exercise prices set at substantial premiums to the current share price and vesting between July 2026 and July 2028. The Board positions the grant as a key retention and incentive tool as the company scales its biometrics service line, which has already secured three contracts within six months of Thissen’s appointment, supporting its wider strategy to drive growth and move towards cash generation.

Physiomics Secures Follow-On Contract for Rheumatoid Arthritis Study

Physiomics plc has secured a follow-on contract with a UK-based client to support a Phase 2 clinical study for a small molecule therapeutic targeting rheumatoid arthritis. The project, set to commence in 2027, underscores Physiomics’ commitment to providing valuable insights for the client’s clinical trial and expanding its project pipeline for the next financial year. The contract, valued between £116K and £169K, highlights the company’s strategic positioning in the biostatistics and data science industry.

Physiomics Secures New Contract with Numab Therapeutics for Antibody Development

Physiomics plc announced a new contract with Numab Therapeutics AG to support the pre-clinical development of a multi-specific antibody for autoimmune diseases. This collaboration will involve developing a mechanistic PK/PD model to enhance understanding of the drug’s behavior and inform dosing decisions for preclinical and clinical studies. The project highlights the significance of Model Informed Drug Development in the drug development lifecycle, reinforcing Physiomics’ role in advancing therapeutic antibody pipelines for both oncology and autoimmune indications.

Physiomics Secures New Contract with GARDP to Enhance Efficacy Trial Design

Physiomics plc has secured a new contract with GARDP Foundation to provide consultancy support for optimizing the design of an efficacy trial in the Serious Bacterial Infections programme. This contract marks a significant milestone for Physiomics’ Biometrics department, being the third contract since its launch and indicating the department’s potential contribution to the company’s growth. The project aligns with Physiomics’ mission to support clinical development planning and expands its reach into the infectious disease therapeutic area.

Physiomics CEO Resignation and Strategic Progress

Physiomics plc announced the resignation of Peter Sargent as CEO, effective May 2026, with Dr. Jim Millen stepping in as Executive Chairman to ensure continuity. The company remains on track with its revenue expectations and continues to progress in its growth initiatives, including a new biometrics service line and advancements in personalized medicine dosing software.

Physiomics CEO Resignation and Leadership Transition

Physiomics plc announced the resignation of CEO Peter Sargent, effective May 29, 2026, as he pursues other opportunities. The company is actively searching for a new CEO, with Dr. Jim Millen, the current Non-Executive Chairman, stepping in as Executive Chairman if needed to ensure continuity. Under Sargent’s leadership, Physiomics achieved significant revenue growth and contract wins, and the company is poised to continue its growth trajectory with a record level of contracted projects and advancements in its personalized medicine initiatives.

Physiomics plc Successfully Passes All AGM Resolutions

Physiomics plc announced that all resolutions presented at its annual general meeting were successfully passed, including the approval of accounts, re-election of directors, and authority to allot shares. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives in the biotech and pharma sectors.

Physiomics Announces Details of Upcoming AGM

Physiomics plc has announced the details of its upcoming Annual General Meeting (AGM), scheduled for 18 November 2025. Shareholders will receive either printed copies or notifications to access the AGM notice and the company’s Annual Report online. This announcement underscores Physiomics’ commitment to maintaining transparency and engagement with its stakeholders, which is crucial for its continued success and industry positioning.